EU and US could reach trade deal this weekend - Reuters
Thermo Fisher Scientific Inc. (NYSE:TMO) stock has reached a 52-week low, touching down at $491.25. According to InvestingPro data, the company, with its substantial $184.8 billion market capitalization, is currently trading at Fair Value levels. This significant dip comes amidst a challenging year for the company, with the stock experiencing a 1-year change decrease of -15.66%. Investors are closely monitoring Thermo Fisher’s performance as it navigates through market fluctuations and sector-specific headwinds. Despite trading at a P/E ratio of 30.25, analyst consensus remains bullish, with price targets ranging from $560 to $767. The company maintains a "GOOD" financial health score, as revealed by InvestingPro’s comprehensive analysis, which includes over 10 additional exclusive insights and a detailed Pro Research Report available to subscribers.
In other recent news, Solventum has agreed to sell its Purification & Filtration business to Thermo Fisher Scientific for $4.1 billion. This transaction is expected to be neutral to Solventum’s earnings per share in 2025, with the company planning to use the approximately $3.4 billion in net proceeds primarily for debt reduction. The sale aligns with Solventum’s strategy to enhance its financial metrics and strategic focus. Trian Fund Management, an activist investor with a 5% stake in Solventum, has advocated for such divestments to reduce costs and improve profitability. Trian has suggested that Solventum should further separate its dental and software businesses to concentrate on its medical and surgical unit. Meanwhile, Thermo Fisher’s acquisition of the Purification & Filtration business is expected to bolster its bioproduction capabilities. The deal is anticipated to close by the end of 2025, pending regulatory approvals. Additionally, Thermo Fisher has announced a 10% increase in its quarterly dividend to $0.43 per share, reflecting its strong financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.